Key Points
- Director Raman Singh sold 8,468 Liquidia shares at an average price of $66.16, generating $560,242.88 and reducing his direct ownership by 15.95%. He also sold 9,024 shares three days earlier.
- Liquidia reported quarterly revenue of $171.68 million, up 1,842.1% year over year, though earnings of $0.74 per share fell short of analyst expectations by $0.02.
- The stock opened at $65.72 with a market capitalization of $5.88 billion. Analysts’ consensus rating is “Hold”, with an average price target of $98.08, while institutional investors own 64.54% of the company.
Liquidia Corporation (NASDAQ:LQDA - Get Free Report) Director Raman Singh sold 8,468 shares of the stock in a transaction that occurred on Monday, September 14th. The shares were sold at an average price of $66.16, for a total transaction of $560,242.88. Following the transaction, the director directly owned 44,637 shares of the company's stock, valued at $2,953,183.92. This represents a 15.95% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink.
Raman Singh also recently made the following trade(s):
- On Friday, September 11th, Raman Singh sold 9,024 shares of Liquidia stock. The stock was sold at an average price of $68.62, for a total transaction of $619,226.88.
Liquidia Trading Up 0.6%
NASDAQ:LQDA opened at $65.72 on Wednesday. The company has a current ratio of 2.31, a quick ratio of 2.12 and a debt-to-equity ratio of 0.63. The stock has a market capitalization of $5.88 billion, a PE ratio of 47.97 and a beta of 0.53. The firm's 50 day moving average is $76.88 and its 200 day moving average is $59.93. Liquidia Corporation has a 12 month low of $21.15 and a 12 month high of $93.61.
Liquidia (NASDAQ:LQDA - Get Free Report) last posted its quarterly earnings data on Wednesday, August 12th. The company reported $0.74 EPS for the quarter, missing the consensus estimate of $0.76 by ($0.02). Liquidia had a net margin of 30.74% and a return on equity of 149.65%. The firm had revenue of $171.68 million during the quarter, compared to analysts' expectations of $168.48 million. During the same quarter in the previous year, the company posted ($0.49) EPS. Liquidia's revenue for the quarter was up 1842.1% on a year-over-year basis. Sell-side analysts expect that Liquidia Corporation will post 2.57 earnings per share for the current year.
Wall Street Analysts Forecast Growth
A number of research analysts have recently commented on the company. HC Wainwright set a $36.00 price target on Liquidia in a research report on Friday, July 24th. Raymond James Financial restated a "strong-buy" rating and issued a $106.00 price objective on shares of Liquidia in a research note on Thursday, August 13th. BTIG Research upped their price objective on shares of Liquidia from $109.00 to $111.00 and gave the company a "buy" rating in a report on Wednesday, August 12th. Wall Street Zen downgraded shares of Liquidia from a "buy" rating to a "hold" rating in a report on Saturday. Finally, Weiss Ratings reiterated a "sell (d-)" rating on shares of Liquidia in a research report on Friday, July 17th. One analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating, three have given a Hold rating and two have given a Sell rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of "Hold" and an average target price of $98.08.
View Our Latest Stock Report on LQDA
Institutional Investors Weigh In On Liquidia
Institutional investors have recently made changes to their positions in the stock. Bank of New York Mellon Corp purchased a new stake in shares of Liquidia in the 2nd quarter valued at about $29,694,000. Bank of America Corp DE grew its holdings in shares of Liquidia by 18.7% during the first quarter. Bank of America Corp DE now owns 2,287,792 shares of the company's stock worth $86,341,000 after purchasing an additional 360,372 shares in the last quarter. Capricorn Fund Managers Ltd purchased a new position in shares of Liquidia during the first quarter worth about $9,337,000. T3 Companies LLC purchased a new position in shares of Liquidia during the fourth quarter worth about $6,084,000. Finally, Eversept Partners LP increased its position in shares of Liquidia by 33.0% in the first quarter. Eversept Partners LP now owns 677,392 shares of the company's stock worth $25,565,000 after purchasing an additional 167,949 shares during the last quarter. Hedge funds and other institutional investors own 64.54% of the company's stock.
About Liquidia
(
Get Free Report)
Liquidia Corporation is a biopharmaceutical company focused on developing and commercializing medicines for patients with serious cardiopulmonary conditions, including pulmonary arterial hypertension (PAH). The company is headquartered in Research Triangle Park, North Carolina, and serves healthcare providers and patients primarily in the United States.
Liquidia's lead product is Yutrepia, an inhaled formulation of treprostinil designed for the treatment of PAH. The company has also developed treprostinil injection products and is pursuing additional therapies for rare cardiopulmonary diseases.
See Also
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
